This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
zika virus | 1622 |
study design | 529 |
case studies | 483 |
background case | 481 |
zikv infection | 391 |
design method | 387 |
results finding | 375 |
virus infection | 356 |
public health | 190 |
blood bank | 188 |
red blood | 176 |
ns pro | 169 |
pregnant women | 162 |
whole blood | 156 |
results findings | 144 |
design methods | 138 |
blood donors | 137 |
ebola virus | 135 |
sexual transmission | 134 |
west nile | 124 |
dengue virus | 118 |
blood center | 118 |
natural products | 112 |
infectious diseases | 104 |
nile virus | 103 |
blood cells | 102 |
blood products | 101 |
respiratory syndrome | 99 |
united states | 95 |
red cell | 93 |
blood cell | 92 |
viral rna | 88 |
blood group | 87 |
zika ns | 85 |
infectious disease | 81 |
blood components | 79 |
vertical transmission | 79 |
yellow fever | 78 |
aedes aegypti | 76 |
rbc units | 76 |
mg dl | 74 |
virus disease | 74 |
transfusion medicine | 73 |
blood transfusion | 72 |
immune response | 71 |
vero cells | 70 |
clinical trials | 70 |
spinal cord | 67 |
blood product | 67 |
vaccine development | 66 |
transfusion service | 65 |
infected cells | 63 |
zikv rna | 62 |
neutralizing antibodies | 62 |
flow cytometry | 61 |
middle east | 61 |
french polynesia | 61 |
performed using | 60 |
blood donor | 57 |
health organization | 57 |
type i | 56 |
medical center | 56 |
blood donation | 56 |
doc id | 55 |
cord uid | 55 |
room temperature | 54 |
transfusion reactions | 54 |
antibody screen | 54 |
rhce ce | 54 |
mouse model | 54 |
east respiratory | 54 |
congenital zika | 53 |
stem cell | 52 |
antiviral activity | 52 |
emerging infectious | 51 |
ng ml | 51 |
world health | 50 |
zikv strains | 50 |
health care | 49 |
nucleic acid | 48 |
acute respiratory | 48 |
platelet count | 48 |
viral loads | 47 |
viral replication | 46 |
animal models | 46 |
red cells | 46 |
center background | 46 |
significantly higher | 46 |
viral infections | 46 |
nervous system | 46 |
birth defects | 45 |
massive transfusion | 45 |
severe acute | 45 |
neutralizing antibody | 45 |
quality control | 44 |
motor deficits | 44 |
virus transmission | 44 |
nk cells | 43 |
virus replication | 43 |
abo rh | 43 |
immune responses | 43 |
virus outbreak | 43 |
viral load | 43 |
blood centers | 42 |
zika fever | 42 |
testicular tissue | 42 |
ag mice | 42 |
blood donations | 42 |
peripheral blood | 42 |
risk factors | 41 |
days post | 41 |
statistically significant | 41 |
cell culture | 41 |
positive samples | 40 |
monoclonal antibodies | 40 |
syndrome coronavirus | 40 |
significant difference | 40 |
pathogen reduction | 40 |
viral genome | 40 |
zika syndrome | 40 |
south america | 39 |
viral genomes | 39 |
body weight | 39 |
chikungunya virus | 39 |
stem cells | 39 |
clinically significant | 39 |
blood samples | 38 |
may also | 38 |
blood type | 38 |
rbc transfusion | 38 |
blood supply | 37 |
patient care | 37 |
zikv replication | 37 |
central nervous | 37 |
er stress | 37 |
genome sequencing | 37 |
mosquito bites | 37 |
zika infection | 36 |
systematic review | 36 |
red cross | 36 |
apheresis platelets | 36 |
blood services | 36 |
clinical trial | 35 |
immune cells | 35 |
endothelial cells | 35 |
cerebrospinal fluid | 35 |
infected individuals | 35 |
virus infections | 34 |
pregnant mice | 34 |
cell death | 34 |
global health | 34 |
natural product | 34 |
virus vaccine | 34 |
zika outbreak | 34 |
deep sequencing | 34 |
sickle cell | 34 |
inhibitory activity | 34 |
blood loss | 34 |
viral infection | 34 |
blood volume | 33 |
influenza virus | 33 |
amniotic fluid | 33 |
adverse events | 33 |
virus zika | 33 |
previously described | 33 |
dna vaccine | 32 |
way anova | 32 |
japanese encephalitis | 32 |
antibody titers | 32 |
within hours | 32 |
previously reported | 32 |
significant differences | 31 |
aegypti mosquitoes | 31 |
rhesus macaques | 31 |
innate immune | 31 |
infected mice | 31 |
medical record | 31 |
disease control | 30 |
dnk cells | 30 |
patient blood | 30 |
cd cells | 29 |
mg kg | 29 |
zika viruses | 29 |
spectrum antiviral | 29 |
copies ml | 29 |
transfusion vol | 29 |
transfusion reaction | 29 |
zikv challenge | 29 |
molecular testing | 29 |
virus rna | 28 |
generation sequencing | 28 |
target enrichment | 28 |
zika vaccine | 28 |
total number | 28 |
health emergency | 28 |
yap island | 28 |
fetal interface | 28 |
avian influenza | 28 |
plasma exchange | 28 |
aedes mosquitoes | 28 |
viral diseases | 27 |
blood banks | 27 |
hemolytic transfusion | 27 |
patient samples | 27 |
fever virus | 27 |
symptom onset | 27 |
west africa | 27 |
results suggest | 27 |
breast milk | 27 |
transfusion services | 27 |
treated mice | 27 |
blood management | 27 |
vector control | 27 |
immune system | 27 |
reverse transcription | 27 |
cell lines | 27 |
virus associated | 26 |
phase i | 26 |
one year | 26 |
cell disease | 26 |
high titer | 26 |
blood component | 26 |
zikv inoculation | 25 |
ic values | 25 |
cell types | 25 |
antibody identification | 25 |
monoclonal antibody | 25 |
adverse effects | 25 |
barre syndrome | 25 |
optimal control | 25 |
american red | 25 |
reproductive number | 25 |
zikv strain | 25 |
puerto rico | 25 |
zikv mr | 25 |
patient safety | 25 |
weight loss | 25 |
drug resistance | 24 |
flow cytometric | 24 |
month period | 24 |
year old | 24 |
bone marrow | 24 |
lethal mutagenesis | 24 |
zikv proteins | 24 |
motor neurons | 24 |
host cell | 24 |
live attenuated | 24 |
electronic medical | 24 |
bact alert | 24 |
positive results | 24 |
zikv ns | 23 |
algan gan | 23 |
platelet concentrates | 23 |
human population | 23 |
virus pathogenesis | 23 |
endoplasmic reticulum | 23 |
encephalitis virus | 23 |
class i | 23 |
pro complexes | 23 |
test results | 23 |
analyzed using | 23 |
two different | 23 |
blood safety | 23 |
data sharing | 23 |
neutralizing activities | 23 |
results showed | 23 |
zika transmission | 23 |
vaccine candidates | 23 |
thermo fisher | 23 |
body fluids | 23 |
human immunodeficiency | 22 |
storage containers | 22 |
platelet counts | 22 |
serum samples | 22 |
first trimester | 22 |
study period | 22 |
units transfused | 22 |
cell line | 22 |
male mice | 22 |
aedes albopictus | 22 |
see table | 22 |
transfusion practice | 22 |
ebola outbreak | 22 |
dependent enhancement | 22 |
one health | 22 |
ns protease | 22 |
clinical practice | 22 |
international concern | 22 |
false positive | 22 |
three times | 22 |
virus genome | 22 |
information system | 22 |
inflammatory response | 22 |
significantly different | 22 |
pregnancy outcomes | 22 |
cord blood | 21 |
immunodeficiency virus | 21 |
reference laboratory | 21 |
new york | 21 |
least one | 21 |
virus ns | 21 |
endemic areas | 21 |
virus infects | 21 |
donor center | 21 |
regional blood | 21 |
fruit bats | 21 |
real time | 21 |
sexually transmitted | 21 |
human cytomegalovirus | 21 |
emergency department | 21 |
frozen plasma | 21 |
animal model | 21 |
hemolytic anemia | 21 |
birth weight | 21 |
increased risk | 21 |
hong kong | 21 |
intensive care | 20 |
serologic testing | 20 |
zika forest | 20 |
platelet products | 20 |
cell viability | 20 |
zikv diagnostics | 20 |
scd patients | 20 |
zikv ediii | 20 |
inventory management | 20 |
case report | 20 |
per month | 20 |
case study | 20 |
iu ml | 20 |
pandemic influenza | 20 |
life cycle | 20 |
retrospective study | 20 |
time pcr | 20 |
basic reproductive | 20 |
plasma samples | 20 |
transfusion protocol | 20 |
dengue fever | 20 |
statistical significance | 20 |
trauma patients | 20 |
disease outbreaks | 20 |
time period | 20 |
antibody response | 20 |
present study | 20 |
significantly lower | 20 |
rna viruses | 20 |
mayo clinic | 20 |
control measures | 20 |
per year | 20 |
bacterial contamination | 20 |
transmission dynamics | 19 |
peer review | 19 |
human infection | 19 |
platelet inventory | 19 |
cells infected | 19 |
envelope protein | 19 |
host immune | 19 |
incubation period | 19 |
pro complex | 19 |
commercially available | 19 |
disease transmission | 19 |
neutralizing activity | 19 |
time points | 19 |
apheresis platelet | 19 |
i interferon | 19 |
preterm birth | 19 |
dengue viruses | 19 |
plasma units | 19 |
log copies | 19 |
well plates | 19 |
lumbosacral spinal | 19 |
des cas | 19 |
therapeutic plasma | 19 |
saudi arabia | 19 |
rhd gene | 19 |
cd deficiency | 19 |
samples tested | 19 |
canadian blood | 19 |
deferral rates | 19 |
blood collection | 19 |
virus type | 18 |
mice treated | 18 |
amino acid | 18 |
treated cells | 18 |
virus isolate | 18 |
zikv infections | 18 |
rare donor | 18 |
rbc transfusions | 18 |
risk factor | 18 |
antiviral activities | 18 |
low birth | 18 |
neurological complications | 18 |
water storage | 18 |
dengue vaccine | 18 |
borne transmission | 18 |
shelf life | 18 |
federated states | 18 |
patients received | 18 |
hospital transfusion | 18 |
statistical analysis | 18 |
university hospital | 18 |
national blood | 18 |
platelet transfusion | 18 |
zikv activity | 18 |
evaluated using | 18 |
platelet units | 18 |
next generation | 18 |
antigen expression | 18 |
risk assessment | 18 |
first time | 18 |
usutu virus | 18 |
significantly increased | 17 |
high levels | 17 |
borne diseases | 17 |
monoclonal anti | 17 |
total rna | 17 |
immunosuppressed mice | 17 |
latin america | 17 |
donor screening | 17 |
neural stem | 17 |
human placental | 17 |
serological specificity | 17 |
human monoclonal | 17 |
rhd beadchip | 17 |
host cells | 17 |
sertoli cells | 17 |
type ii | 17 |
zika epidemic | 17 |
treated rbcs | 17 |
small number | 17 |
hospital background | 17 |
plaque assay | 17 |
intrauterine infection | 17 |
pathogen inactivation | 17 |
rejuvenation solution | 17 |
virus particles | 17 |
female donors | 17 |
emerging viral | 17 |
severe disease | 17 |
eu eea | 17 |
negative control | 17 |
ediii protein | 17 |
vitro quality | 17 |
hcmv infection | 17 |
congenital anomalies | 17 |
blood ordering | 17 |
first isolated | 17 |
iron deficiency | 17 |
west african | 17 |
new automated | 16 |
jamaican fruit | 16 |
novel coronavirus | 16 |
viral proteins | 16 |
solid phase | 16 |
tube testing | 16 |
herpes simplex | 16 |
widely used | 16 |
vaccine design | 16 |
pfu ml | 16 |
manual tube | 16 |
progenitor cells | 16 |
literature review | 16 |
nk cell | 16 |
fetal brain | 16 |
inhibit zikv | 16 |
viral entry | 16 |
zika igg | 16 |
antibody screening | 16 |
neural progenitor | 16 |
case series | 16 |
genital tract | 16 |
virus epidemic | 16 |
two groups | 16 |
blood service | 16 |
serial dilutions | 16 |
genomic dna | 16 |
clinical outcomes | 16 |
infected patients | 16 |
serially diluted | 16 |
two independent | 16 |
tertiary care | 16 |
volume reduction | 16 |
control study | 16 |
placental barrier | 16 |
repeat testing | 16 |
cell responses | 16 |
within days | 16 |
leucocyte depleted | 16 |
high prevalence | 16 |
neural progenitors | 16 |
pediatric patients | 16 |
blood system | 16 |
fresh frozen | 16 |
donor samples | 16 |
zikv transmission | 16 |
brain endothelial | 16 |
even though | 16 |
white blood | 15 |
human skin | 15 |
vaccine platforms | 15 |
dtt treatment | 15 |
authors declare | 15 |
endemic regions | 15 |
stored rbcs | 15 |
antiglobulin test | 15 |
membrane fusion | 15 |
voluntary blood | 15 |
phase iii | 15 |
high electron | 15 |
protective efficacy | 15 |
additive solution | 15 |
pregnant woman | 15 |
cd cd | 15 |
olfactory ensheathing | 15 |
marburg virus | 15 |
unfolded protein | 15 |
vast majority | 15 |
asian lineage | 15 |
phylogenetic analysis | 15 |
clinical studies | 15 |
mosquito species | 15 |
hematopoietic stem | 15 |
patients receiving | 15 |
also known | 15 |
genomic data | 15 |
chain reaction | 15 |
future studies | 15 |
negative blood | 15 |
phase ii | 15 |
rbcs stored | 15 |
ns protein | 15 |
vaccine candidate | 15 |
emerging viruses | 15 |
aedes mosquito | 15 |
fetal demise | 15 |
rbc unit | 15 |
strain prvabc | 15 |
brazil zika | 15 |
specific mabs | 15 |
significant increase | 15 |
graphpad prism | 15 |
infects human | 15 |
ferritin levels | 15 |
neurological disorders | 15 |
virus detection | 15 |
cell cultures | 15 |
terumo bct | 15 |
low levels | 15 |
mrna vaccines | 15 |
likely due | 15 |
antiviral agents | 15 |
reagent red | 15 |
rna copies | 15 |
fisher scientific | 15 |
polymerase chain | 15 |
large number | 15 |
mouse models | 15 |
drug administration | 15 |
rhesus macaque | 15 |
rhd diiia | 15 |
logistic regression | 15 |
implementing partners | 15 |
crystal structure | 15 |
electron mobility | 15 |
natural vertical | 15 |
amotosalen uva | 15 |
rhesus monkeys | 15 |
infectious zika | 15 |
control strategies | 14 |
emergency blood | 14 |
fda approved | 14 |
significant antibodies | 14 |
zikv neonates | 14 |
retrospective review | 14 |
turnaround time | 14 |
whole genome | 14 |
sierra leone | 14 |
syndrome outbreak | 14 |
hemolytic disease | 14 |
buffy coat | 14 |
viral particles | 14 |
best practices | 14 |
independent experiments | 14 |
treated zikv | 14 |
blood systems | 14 |
virus strain | 14 |
health system | 14 |
iron metabolism | 14 |
tissue tropism | 14 |
emergency release | 14 |
zika cases | 14 |
viral pathogens | 14 |
nucleic acids | 14 |
dexamethasone immunosuppression | 14 |
adverse pregnancy | 14 |
blood transfusions | 14 |
zika vrna | 14 |
dengue ns | 14 |
reverse transcriptase | 14 |
flaviviral ns | 14 |
significant impact | 14 |
cytomegalovirus infection | 14 |
inhibits zika | 14 |
donor population | 14 |
hemoglobin levels | 14 |
sciatic nerve | 14 |
human serum | 14 |
male donors | 14 |
direct antiglobulin | 14 |
vaccine clinical | 14 |
linear regression | 14 |
tube method | 14 |
developing fetus | 14 |
care providers | 14 |
may affect | 14 |
rapid spread | 14 |
infection zika | 14 |
human neutralizing | 14 |
negative rbcs | 14 |
human primates | 14 |
severe neurological | 14 |
quality improvement | 14 |
primary human | 14 |
salivary gland | 14 |
neg rbc | 14 |
blood screening | 14 |
antibody screens | 14 |
inhibit zika | 14 |
pathogen reduced | 14 |
rna replication | 14 |
rbc products | 14 |
specific antibody | 14 |
tested positive | 14 |
comparator assay | 14 |
spinal motor | 14 |
outbreak associated | 14 |
gan high | 14 |
breast cancer | 14 |
human plasma | 14 |
zikv ir | 14 |
pathogen surveillance | 14 |
resistant variants | 14 |
utr regions | 14 |
serum albumin | 13 |
protein expression | 13 |
care unit | 13 |
transfusion transmitted | 13 |
protein response | 13 |
genetic variants | 13 |
metagenomic sequencing | 13 |
congenital infection | 13 |
single unit | 13 |
standard deviation | 13 |
genotyping results | 13 |
chloroquine treatment | 13 |
antiviral drugs | 13 |
university school | 13 |
trauma center | 13 |
healthy adults | 13 |
first report | 13 |
rna virus | 13 |
i ii | 13 |
average number | 13 |
like activity | 13 |
dna sequencing | 13 |
ebola epidemic | 13 |
pluripotent stem | 13 |
low ferritin | 13 |
phenyl ring | 13 |
clinical samples | 13 |
different cell | 13 |
infectious virus | 13 |
inhibits zikv | 13 |
days later | 13 |
viral pandemics | 13 |
tested using | 13 |
mononuclear cells | 13 |
one unit | 13 |
motor cortex | 13 |
side effects | 13 |
storage lesion | 13 |
intrauterine infections | 13 |
donated blood | 13 |
irradiated blood | 13 |
confirmed positive | 13 |
congenital malformations | 13 |
standard tube | 13 |
forming units | 13 |
positive control | 13 |
adverse reactions | 13 |
simplex virus | 13 |
hla antibodies | 13 |
phase clinical | 13 |
stress granules | 13 |
strains tested | 13 |
similar results | 13 |
endemic equilibrium | 13 |
cost savings | 13 |
one patient | 13 |
clinical symptoms | 13 |
one study | 13 |
commonly used | 13 |
transfusion testing | 13 |
final concentration | 13 |
human igg | 13 |
cell transplantation | 13 |
one hour | 13 |
rhd genotyping | 13 |
transfused patients | 13 |
laboratory testing | 13 |
trophoblast cells | 13 |
sperm count | 13 |
per unit | 13 |
purified inactivated | 13 |
virus entry | 13 |
based transfusion | 12 |
replacement fluid | 12 |
mosquito populations | 12 |
asymptotically stable | 12 |
nat yield | 12 |
patient population | 12 |
high risk | 12 |
patients undergoing | 12 |
disease prevention | 12 |
results indicate | 12 |
years old | 12 |
local transmission | 12 |
genome replication | 12 |
health authorities | 12 |
interferon signaling | 12 |
western hemisphere | 12 |
group system | 12 |
hbv dna | 12 |
rna polymerase | 12 |
cells may | 12 |
brain barrier | 12 |
per patient | 12 |
borne viruses | 12 |
thawed plasma | 12 |
sars coronavirus | 12 |
seminiferous tubules | 12 |
altered infectivity | 12 |
hcmv infected | 12 |
human health | 12 |
clinical development | 12 |
reproduction number | 12 |
control group | 12 |
disease surveillance | 12 |
preventive behaviors | 12 |
academic medical | 12 |
umbilical cord | 12 |
structural proteins | 12 |
blood supplier | 12 |
positive cells | 12 |
antigen negative | 12 |
possible association | 12 |
study zika | 12 |
clinically relevant | 12 |
predicted phenotype | 12 |
time course | 12 |
pan american | 12 |
mutation frequencies | 12 |
using two | 12 |
central america | 12 |
kir ds | 12 |
pilot study | 12 |
syncytial virus | 12 |
hcv rna | 12 |
respiratory syncytial | 12 |
false negative | 12 |
blood sample | 12 |
rhd negative | 12 |
buffered saline | 12 |
american health | 12 |
congenital zikv | 12 |
neutralizing mabs | 12 |
vps score | 12 |
lessons learned | 12 |
hemorrhagic fever | 12 |
log ec | 12 |
based blood | 12 |
human brain | 12 |
high throughput | 12 |
er membrane | 12 |
based vaccines | 12 |
protein folding | 12 |
analysis revealed | 12 |
better understand | 12 |
immature platelet | 12 |
enveloped viruses | 12 |
inhibited zikv | 12 |
old female | 12 |
management system | 12 |
ml kg | 12 |
dendritic cells | 12 |
alloimmunized patients | 12 |
ion torrent | 12 |
family members | 12 |
transfusion recipients | 12 |
also tested | 12 |
virus strains | 12 |
cells ml | 12 |
clinical manifestations | 12 |
affected areas | 12 |
hospital blood | 12 |
reactive samples | 12 |
genomic epidemiology | 12 |
donate blood | 12 |
case reports | 12 |
rhesus monkey | 12 |
rhd weak | 12 |
hours post | 12 |
sanger sequencing | 12 |
regression analysis | 12 |
bodily fluids | 12 |
pandemic preparedness | 11 |
vector competence | 11 |
southeast asia | 11 |
zikv may | 11 |
cd cell | 11 |
antigen typing | 11 |
study demonstrated | 11 |
working group | 11 |
neutralize zikv | 11 |
virus may | 11 |
recent studies | 11 |
plt count | 11 |
emergency use | 11 |
samples collected | 11 |
neuroglial cells | 11 |
disease outbreak | 11 |
dpg levels | 11 |
retrospective analysis | 11 |
facs buffer | 11 |
untranslated regions | 11 |
african americans | 11 |
antibody titer | 11 |
human cases | 11 |
prevent zika | 11 |
host factors | 11 |
high frequency | 11 |
dna polymerase | 11 |
compatible blood | 11 |
critically ill | 11 |
antibody responses | 11 |
virus titers | 11 |
like illness | 11 |
hydrogen bond | 11 |
different time | 11 |
automated bp | 11 |
perinatal transmission | 11 |
apheresis donors | 11 |
transfusion safety | 11 |
multiple comparison | 11 |
viral wgs | 11 |
may occur | 11 |
much lower | 11 |
within weeks | 11 |
buffy coats | 11 |
split rate | 11 |
cohort study | 11 |
structural basis | 11 |
abo typing | 11 |
zikv compound | 11 |
response rate | 11 |
post thaw | 11 |
calculated based | 11 |
man bsaas | 11 |
crystal violet | 11 |
three days | 11 |
technician related | 11 |
human mabs | 11 |
ensheathing cells | 11 |
prospective study | 11 |
phone calls | 11 |
cxcr pd | 11 |
human cd | 11 |
cell migration | 11 |
important role | 11 |
zikv infected | 11 |
significantly reduced | 11 |
rights reserved | 11 |
may help | 11 |
dependent manner | 11 |
determined using | 11 |
disease epidemics | 11 |
kindly provided | 11 |
mean age | 11 |
among blood | 11 |
patient harm | 11 |
large volume | 11 |
larvae pools | 11 |
nip rhd | 11 |
plasma replacement | 11 |
titer anti | 11 |
epithelial cells | 11 |
may provide | 11 |
new world | 11 |
preprint posting | 11 |
among men | 11 |
viral sequences | 11 |
donor plasma | 11 |
hb deferral | 11 |
tissue culture | 11 |
cd tregs | 11 |
unfolded proteins | 11 |
specificity zika | 11 |
breeding sites | 11 |
patients requiring | 11 |
hematology analyzer | 11 |
transplant recipients | 11 |
multiple myeloma | 11 |
human coronavirus | 11 |
zikv outbreak | 11 |
automated alinity | 11 |
may include | 11 |
hod otii | 11 |
platelet transfusions | 11 |
persistent infection | 11 |
differential equations | 11 |
google trends | 11 |
limited data | 11 |
determine whether | 11 |
denv infection | 11 |
human neural | 11 |
inhibitory effects | 11 |
plaque reduction | 11 |
molecular weight | 11 |
flaviviridae family | 11 |
gastrocnemius muscle | 11 |
rh typing | 11 |
course study | 11 |
reference laboratories | 11 |
cell processor | 11 |
ab plasma | 11 |
antenatal care | 11 |
human transmission | 11 |
virus dna | 11 |
diagnostic tests | 11 |
influenza viruses | 11 |
antiviral agent | 11 |
developing fetuses | 11 |
health emergencies | 11 |
tranexamic acid | 11 |
iron depletion | 11 |
interferon treatment | 11 |
strain pan | 11 |
zika pandemic | 11 |
recent years | 11 |
cell units | 11 |
electron microscopy | 10 |
wide range | 10 |
time point | 10 |
platelet recovery | 10 |
fatality rate | 10 |
hindlimb motor | 10 |
donor unit | 10 |
mass spectrometry | 10 |
abo bw | 10 |
rbc alloimmunization | 10 |
virus challenge | 10 |
coinfected mosquitoes | 10 |
last years | 10 |
gene sequences | 10 |
result verification | 10 |
titer results | 10 |
micronesia zika | 10 |
weeks old | 10 |
data management | 10 |
measured using | 10 |
hydroxyl group | 10 |
controlled trial | 10 |
several studies | 10 |
studies showed | 10 |
pacific islands | 10 |
febrile illness | 10 |
away time | 10 |
current status | 10 |
bovine serum | 10 |
study demonstrates | 10 |
maternal immune | 10 |
pathogenic mutations | 10 |
borne virus | 10 |
data suggest | 10 |
first described | 10 |
also observed | 10 |
potent neutralizing | 10 |
rbc alloantibodies | 10 |
limited number | 10 |
baby units | 10 |
data collection | 10 |
zkv testing | 10 |
us blood | 10 |
global spread | 10 |
per week | 10 |
female mice | 10 |
packed red | 10 |
digital epidemiology | 10 |
creative commons | 10 |
blood pressure | 10 |
three different | 10 |
flavivirus infection | 10 |
blood groups | 10 |
mers coronavirus | 10 |
sample collection | 10 |
see note | 10 |
reproductive tract | 10 |
human strains | 10 |
positive antibody | 10 |
peg iat | 10 |
replication cycle | 10 |
htlv i | 10 |
laboratory data | 10 |
rna extraction | 10 |
duke university | 10 |
mosquito vectors | 10 |
patient received | 10 |
artificial intelligence | 10 |
health surveillance | 10 |
listeria monocytogenes | 10 |
may lead | 10 |
high specificity | 10 |
asian genotype | 10 |
zikv envelope | 10 |
significantly decreased | 10 |
ill patients | 10 |
inactivated zika | 10 |
infants born | 10 |
detection limit | 10 |
viral vectors | 10 |
stored rbc | 10 |
slightly higher | 10 |
novel antiviral | 10 |
zikv particles | 10 |
antiviral drug | 10 |
storage period | 10 |
ttp patients | 10 |
serologic weak | 10 |
may require | 10 |
zikv isolates | 10 |
patients may | 10 |
virus ebola | 10 |
study aimed | 10 |
sciatic notch | 10 |
cross blood | 10 |
viral disease | 10 |
five days | 10 |
mobility transistors | 10 |
acute phase | 10 |
blood specimens | 10 |
reduced zikv | 10 |
wbc count | 10 |
mosquito bite | 10 |
antibodies isolated | 10 |
infection may | 10 |
tissue sections | 10 |
testing using | 10 |
histological analysis | 10 |
rhd xt | 10 |
open access | 10 |
also performed | 10 |
drug development | 10 |
family planning | 10 |
chart review | 10 |
days prior | 10 |
early stages | 10 |
blood banking | 10 |
tissue factor | 10 |
different zikv | 10 |
congenital cytomegalovirus | 10 |
coronavirus disease | 10 |
new process | 10 |
stranded rna | 10 |
national institutes | 10 |
crossmatch compatible | 10 |
median age | 10 |
dans un | 10 |
way valve | 10 |
also used | 10 |
dans les | 10 |
immunohematology reference | 10 |
cell receptor | 10 |
microcephaly cases | 10 |
endemic countries | 10 |
i interferons | 10 |
er lumen | 10 |
two days | 10 |
negative results | 10 |
zika prevention | 10 |
product wastage | 10 |
childbearing age | 10 |
medicine background | 10 |
cd expression | 10 |
closely related | 10 |
medical records | 10 |
semen samples | 10 |
ap donors | 10 |
patients presenting | 10 |
clinical metagenomics | 10 |
life technologies | 10 |
id rhd | 10 |
apheresis procedures | 10 |
donor program | 10 |
vertically transmitted | 10 |
spectra optia | 10 |
single dose | 10 |
patient identification | 10 |
post collection | 10 |
dengue infection | 10 |
chronically transfused | 10 |
gene sequencing | 10 |
protein kinase | 10 |
pcr products | 10 |
control mice | 10 |
lymph nodes | 10 |
day post | 10 |
interim guidance | 10 |
igg antibody | 10 |
rbc storage | 10 |
single donor | 10 |
may result | 10 |
five flavonoids | 10 |
binding sites | 10 |
fresenius kabi | 10 |
dna vaccines | 10 |
complete genome | 10 |
vector transmission | 10 |
therapeutic potential | 10 |
acute infection | 10 |
platelet additive | 10 |
research institute | 10 |
complete protection | 10 |
virus particle | 10 |
hla class | 10 |
preventive measures | 10 |
com scientificreports | 10 |
using standard | 10 |
unlinked zika | 10 |
ninds nih | 10 |
infectious titer | 9 |
transfusion practices | 9 |
blood order | 9 |
previous study | 9 |
study days | 9 |
week period | 9 |
units per | 9 |
ortho clinical | 9 |
prostate cancer | 9 |
delayed hemolytic | 9 |
inventory levels | 9 |
les mesures | 9 |
laboratory information | 9 |
infection rate | 9 |
health concern | 9 |
mice zika | 9 |
significant reduction | 9 |
comparison tests | 9 |
modelling study | 9 |
final product | 9 |
specific antigen | 9 |
influenza pandemic | 9 |
nat screening | 9 |
platelet adhesion | 9 |
much higher | 9 |
clinical outcome | 9 |
may contribute | 9 |
du virus | 9 |
second sample | 9 |
cells kg | 9 |
natural killer | 9 |
basic reproduction | 9 |
informed consent | 9 |
immucor neo | 9 |
outbreak response | 9 |
surgical blood | 9 |
pandemic potential | 9 |
seasonal influenza | 9 |
within normal | 9 |
low titer | 9 |
genome sequence | 9 |
year period | 9 |
mathematical model | 9 |
suckling mice | 9 |
cmap amplitudes | 9 |
cell surface | 9 |
motor neuron | 9 |
fold increase | 9 |
human pregnancy | 9 |
routine quality | 9 |
candida spp | 9 |
first case | 9 |
neutralizing monoclonal | 9 |
spondweni virus | 9 |
paper sensor | 9 |
liver disease | 9 |
copies per | 9 |
based sensors | 9 |
screening test | 9 |
plasma volume | 9 |
binding affinity | 9 |
lassa fever | 9 |
natural infection | 9 |
plaque forming | 9 |
observational study | 9 |
phase red | 9 |
culture media | 9 |
terminal residues | 9 |
clinical data | 9 |
cases reported | 9 |
rhd variant | 9 |
trima accel | 9 |
gestational age | 9 |
infected mothers | 9 |
another study | 9 |
medium containing | 9 |
laboratory operations | 9 |
bacterial culture | 9 |
candidate vaccines | 9 |
potential benefits | 9 |
three patients | 9 |
two cases | 9 |
safe blood | 9 |
general population | 9 |
treated group | 9 |
exact test | 9 |
first reported | 9 |
women infected | 9 |
human antibody | 9 |
per day | 9 |
par le | 9 |
blood count | 9 |
hla typing | 9 |
pg ml | 9 |
long term | 9 |
protein synthesis | 9 |
high incidence | 9 |
time rt | 9 |
also reported | 9 |
transmembrane protein | 9 |
democratic republic | 9 |
virus genomes | 9 |
binding domain | 9 |
allogeneic blood | 9 |
clone anti | 9 |
patient outcomes | 9 |
improve patient | 9 |
genus flavivirus | 9 |
clinical presentation | 9 |
samples obtained | 9 |
yap state | 9 |
using different | 9 |
mesenchymal stem | 9 |
randomized controlled | 9 |
germ cells | 9 |
kidney transplant | 9 |
failed runs | 9 |
hla antibody | 9 |
first months | 9 |
indirect antiglobulin | 9 |
competing interests | 9 |
two additional | 9 |
cortical neural | 9 |
factor viii | 9 |
mhc class | 9 |
molecular mechanisms | 9 |
thrombocytopenic purpura | 9 |
age group | 9 |
blood derived | 9 |
pcr detection | 9 |
studies will | 9 |
laboratories indicated | 9 |
probable non | 9 |
expression levels | 9 |
maculopapular rash | 9 |
zika outbreaks | 9 |
steady state | 9 |
heavy chain | 9 |
platelet collections | 9 |
willebrand factor | 9 |
cell collection | 9 |
aegypti mosquito | 9 |
rhce cehar | 9 |
hsqc peaks | 9 |
transmitted zika | 9 |
case fatality | 9 |
brazilian zika | 9 |
post transfusion | 9 |
clinic background | 9 |
south korea | 9 |
cause severe | 9 |
direct contact | 9 |
viral vector | 9 |
closed system | 9 |
platelet components | 9 |
weeks among | 9 |
sexual contact | 9 |
positive dat | 9 |
rbc antigens | 9 |
better understanding | 9 |
may become | 9 |
clinical signs | 9 |
nucleoside analogues | 9 |
active site | 9 |
liquid plasma | 9 |
among women | 9 |
recent outbreaks | 9 |
uninfected cells | 9 |
teg results | 9 |
disease caused | 9 |
positive donations | 9 |
clinical diagnostics | 9 |
adverse outcomes | 9 |
zikv epidemic | 9 |
organ transplant | 9 |
septic transfusion | 9 |
north america | 9 |
viral nucleic | 9 |
normal limits | 9 |
innate immunity | 9 |
data analysis | 9 |
new virus | 9 |
plasma wastage | 9 |
african american | 9 |
mice infected | 9 |
high volume | 9 |
also demonstrated | 9 |
infectious particles | 9 |
linked immunosorbent | 9 |
rbc exchange | 9 |
surface antigen | 9 |
transmission potential | 9 |
analytical sensitivity | 9 |
one week | 9 |
zika response | 9 |
von willebrand | 9 |
le virus | 9 |
cells using | 9 |
pizv dose | 9 |
autoimmune hemolytic | 9 |
volume processed | 9 |
compound control | 9 |
total blood | 9 |
horizontal transmission | 9 |
van den | 9 |
specific antibodies | 9 |
cerus corporation | 9 |
copy number | 8 |
domain iii | 8 |
transmit zika | 8 |
borne flavivirus | 8 |
cmnc protocol | 8 |
simulated transfusion | 8 |
brain microvascular | 8 |
maternal blood | 8 |
mm tris | 8 |
rare donors | 8 |
scale bar | 8 |
concomitant infections | 8 |
multiple comparisons | 8 |
detect zikv | 8 |
severe dengue | 8 |
ortho vision | 8 |
manufacturing methods | 8 |
data sources | 8 |
platelet usage | 8 |
investigate whether | 8 |
ns gene | 8 |
time consuming | 8 |
markedly reduced | 8 |
analysed using | 8 |
brain abnormalities | 8 |
oneg rbcs | 8 |
genome sequences | 8 |
irradiated rbcs | 8 |
human placenta | 8 |
vector vaccines | 8 |
virus vaccines | 8 |
targeted mabs | 8 |
immune cell | 8 |
previous studies | 8 |
upload time | 8 |
peripheral neuropathy | 8 |
procedure cd | 8 |
among pregnant | 8 |
bl mice | 8 |
currently available | 8 |
cell antibodies | 8 |
based assay | 8 |
immunohistochemical staining | 8 |
iron supplementation | 8 |
standard curve | 8 |
geographic spread | 8 |
million people | 8 |
flow cytometer | 8 |
serologic properties | 8 |
technologist time | 8 |
lipid metabolism | 8 |
immune globulin | 8 |
readily available | 8 |
disease virus | 8 |
many different | 8 |
buffer solution | 8 |
outside africa | 8 |
zika aptamer | 8 |
vero cell | 8 |
rbc samples | 8 |
pbs buffer | 8 |
emergency units | 8 |
viral protein | 8 |
constant control | 8 |
phylogenetic trees | 8 |
thrombotic thrombocytopenic | 8 |
automated solid | 8 |
nucleotide sequence | 8 |
oneg patients | 8 |
disseminated infection | 8 |
severe reaction | 8 |
give blood | 8 |
triglyceride levels | 8 |
detected using | 8 |
whole viral | 8 |
pe group | 8 |
semen parameters | 8 |
seminiferous tubule | 8 |
also showed | 8 |
infection induces | 8 |
igm positive | 8 |
prbc units | 8 |
neutrophil infiltration | 8 |
escherichia coli | 8 |
three cases | 8 |
confidence interval | 8 |
significant decrease | 8 |
united kingdom | 8 |
viral strains | 8 |
primary infection | 8 |
primary hits | 8 |
sbc programming | 8 |
two weeks | 8 |
spectrum anti | 8 |
represent mean | 8 |
infected individual | 8 |
recombinant type | 8 |
infection rates | 8 |
transmission rates | 8 |
time periods | 8 |
light chain | 8 |
using algan | 8 |
several years | 8 |
first step | 8 |
pak lx | 8 |
gel card | 8 |
neutralizing human | 8 |
plaque assays | 8 |
confirmed cases | 8 |
south pacific | 8 |
calculated using | 8 |
four patients | 8 |
rhd alleles | 8 |
fibrinogen levels | 8 |
labeled ns | 8 |
luminex bead | 8 |
approved drugs | 8 |
cytopathic effect | 8 |
human antibodies | 8 |
study shows | 8 |
travel history | 8 |
reported cases | 8 |
immediate spin | 8 |
group ab | 8 |
implementation period | 8 |
also associated | 8 |
process improvement | 8 |
assay buffer | 8 |
septic patients | 8 |
molecular epidemiology | 8 |
barr virus | 8 |
appointment booking | 8 |
pcr reactions | 8 |
rh phenotype | 8 |
hla matched | 8 |
lineage zika | 8 |
linked zika | 8 |
mosquito vector | 8 |
per animal | 8 |
clinical assays | 8 |
pro domain | 8 |
platelet refractoriness | 8 |
flavivirus infections | 8 |
cytometric method | 8 |
information regarding | 8 |
acute zika | 8 |
plt units | 8 |
health professionals | 8 |
tm cells | 8 |
secondary structure | 8 |
affinity maturation | 8 |
product utilization | 8 |
cobe spectra | 8 |
alloimmunization rates | 8 |
world war | 8 |
deficient mice | 8 |
virus structural | 8 |
blood utilization | 8 |
based assays | 8 |
services background | 8 |
transfusion related | 8 |
urine samples | 8 |
ediii proteins | 8 |
effective treatment | 8 |
immunodetection assay | 8 |
virus exposure | 8 |
testicular atrophy | 8 |
preliminary report | 8 |
patients treated | 8 |
brain organoids | 8 |
hgb hct | 8 |
developing countries | 8 |
two distinct | 8 |
personal protection | 8 |
data collected | 8 |
old male | 8 |
drug repurposing | 8 |
phylogenetic tree | 8 |
decidual nk | 8 |
associated microcephaly | 8 |
matched platelets | 8 |
protein concentration | 8 |
encephalitis viruses | 8 |
different stages | 8 |
emergent situations | 8 |
thrombin generation | 8 |
secondary antibody | 8 |
abo blood | 8 |
dna samples | 8 |
liquid chromatography | 8 |
medical director | 8 |
may play | 8 |
transcription factor | 8 |
fold serial | 8 |
digital pathogen | 8 |
bpn bottles | 8 |
viral titers | 8 |
ex vivo | 8 |
pcr amplicon | 8 |
human cortical | 8 |
close proximity | 8 |
suspected cases | 8 |
neurologic complications | 8 |
partial plasma | 8 |
rapid risk | 8 |
seeking behaviors | 8 |
times higher | 8 |
behavior change | 8 |
six compounds | 8 |
confer protection | 8 |
molecular detection | 8 |
national reference | 8 |
culture results | 8 |
orp values | 8 |
specific memory | 8 |
blood mononuclear | 8 |
linked ns | 8 |
antibody levels | 8 |
preterm labor | 8 |
using routine | 8 |
lethal infection | 8 |
study evaluated | 8 |
considered significant | 8 |
alcoholic steatohepatitis | 8 |
group antigen | 8 |
mathematical modeling | 8 |
blood flow | 8 |
clinical use | 8 |
time donors | 8 |
amplicon sequencing | 8 |
following transfusion | 8 |
wastage rates | 8 |
different blood | 8 |
viral persistence | 8 |
human zikv | 8 |
misfolded unfolded | 8 |
ferritin testing | 8 |
host interactions | 8 |
gene expression | 8 |
evidence review | 8 |
three groups | 8 |
rh blood | 8 |
dot represents | 8 |
based methods | 8 |
storage duration | 8 |
mutation frequency | 8 |
climate change | 8 |
emergently issued | 8 |
infected humans | 8 |
cells derived | 8 |
strain mr | 8 |
rabies virus | 8 |
mab binding | 8 |
rna synthesis | 8 |
eggs collected | 8 |
potential sexual | 8 |
ongoing zika | 8 |
mortality rate | 8 |
placental tissues | 8 |
new data | 8 |
surveillance systems | 8 |
medical history | 8 |
specific hits | 8 |
platelet clearance | 8 |
assay performance | 8 |
cell adherence | 8 |
normal saline | 8 |
forward primer | 8 |
transfusion hemoglobin | 8 |
typing results | 8 |
factors associated | 8 |
mosquito repellent | 8 |
skin cells | 8 |
group antigens | 8 |
platelet yield | 8 |
viral titres | 8 |
cell response | 8 |
prevent sexual | 8 |
automated gel | 8 |
significant effect | 8 |
nonhuman primates | 8 |
affected countries | 8 |
zikv exposure | 8 |
hematological parameters | 8 |
protective effect | 8 |
matched units | 8 |
congenital defects | 8 |
transmitted infections | 8 |
healthy donors | 8 |
mp content | 8 |
tpe procedures | 8 |
results show | 8 |
molecular tweezer | 8 |
zikv serology | 7 |
mini kit | 7 |
term storage | 7 |
igm antibodies | 7 |
waste management | 7 |
adult ag | 7 |
george chen | 7 |
four different | 7 |
antiviral therapy | 7 |
adjoint system | 7 |
respiratory infections | 7 |
dara interference | 7 |
prioritization process | 7 |
process steps | 7 |
human fetal | 7 |
social media | 7 |
continuous variables | 7 |
old man | 7 |
testing algorithm | 7 |
total bilirubin | 7 |
olfactory nerve | 7 |
laboratory results | 7 |
assessed using | 7 |
nanopore sequencing | 7 |
mirasol prt | 7 |
operations demand | 7 |
acid test | 7 |
global distribution | 7 |
le diagnostic | 7 |
washed twice | 7 |
true positive | 7 |
weakly positive | 7 |
valley fever | 7 |
transfusion hgb | 7 |
assays perform | 7 |
family flaviviridae | 7 |
analysis using | 7 |
antibodies targeting | 7 |
rheumatoid arthritis | 7 |
healthy volunteers | 7 |
dna extracted | 7 |
acute pancreatitis | 7 |
human cells | 7 |
among patients | 7 |
neutralising antibodies | 7 |
patients infected | 7 |
retrospective cohort | 7 |
cellular responses | 7 |
broadly neutralizing | 7 |
sequence analysis | 7 |
oxygen affinity | 7 |
using gamma | 7 |
ig genes | 7 |
acid testing | 7 |
zikv vaccine | 7 |
model parameters | 7 |
molecular biology | 7 |
water bath | 7 |
flaccid paralysis | 7 |
also inhibits | 7 |
death rate | 7 |
platelet aggregation | 7 |
ic value | 7 |
receptor binding | 7 |
infection using | 7 |
neonatal sepsis | 7 |
donation frequency | 7 |
cell antigens | 7 |
denv serotypes | 7 |
complete blood | 7 |
growth factor | 7 |
recent study | 7 |
serological tests | 7 |
rbc genotyping | 7 |
hospital based | 7 |
log pfu | 7 |
patients showed | 7 |
rift valley | 7 |
iron stores | 7 |
bacterial infection | 7 |
vector population | 7 |
disease patients | 7 |
nonhuman primate | 7 |
rare blood | 7 |
reagent management | 7 |
clinical care | 7 |
sequencing data | 7 |
slightly lower | 7 |
study also | 7 |
brain tissue | 7 |
antibodies directed | 7 |
fort collins | 7 |
mosquito eggs | 7 |
become infected | 7 |
secure texting | 7 |
transmitted infection | 7 |
ct group | 7 |
year following | 7 |
adamts activity | 7 |
zika protease | 7 |
procleix zikv | 7 |
random blood | 7 |
zikv multiplication | 7 |
amino acids | 7 |
interim guidelines | 7 |
data points | 7 |
blood fridge | 7 |
individual donation | 7 |
seizure activity | 7 |
done using | 7 |
coagulation parameters | 7 |
acute flaccid | 7 |
null phenotype | 7 |
two years | 7 |
reduction technology | 7 |
confocal microscopy | 7 |
zikv infects | 7 |
rad laboratories | 7 |
months post | 7 |
renal failure | 7 |
hospital system | 7 |
broad spectrum | 7 |
pneumatic tube | 7 |
serological testing | 7 |
also evaluated | 7 |
scientific community | 7 |
pcr amplification | 7 |
vps scores | 7 |
international travel | 7 |
per milliliter | 7 |
one rbc | 7 |
transmission routes | 7 |
adamts deficiency | 7 |
i tool | 7 |
transfusion support | 7 |
mk cells | 7 |
following zikv | 7 |
first identified | 7 |
age groups | 7 |
measles virus | 7 |
old woman | 7 |
george schlauder | 7 |
knockout mice | 7 |
swab samples | 7 |
experimental models | 7 |
operator touchpoints | 7 |
virus spreads | 7 |
cell activation | 7 |
antibodies prevent | 7 |
animal reservoirs | 7 |
gregg williams | 7 |
high inhibitor | 7 |
binding site | 7 |
icu patients | 7 |
comparative analysis | 7 |
level i | 7 |
syndromic surveillance | 7 |
medicine service | 7 |
en charge | 7 |
placental blood | 7 |
jane bryant | 7 |
dpi inclusively | 7 |
calcusyn computer | 7 |
zikv diagnostic | 7 |
cd yield | 7 |
ost complex | 7 |
army institute | 7 |
highly efficacious | 7 |
greater impact | 7 |
emerging pathogens | 7 |
like syndrome | 7 |
community hospitals | 7 |
five years | 7 |
maximum surgical | 7 |
mers cov | 7 |
mark paradowski | 7 |
obtained using | 7 |
health sciences | 7 |
like receptor | 7 |
ifn signaling | 7 |
fatty acid | 7 |
drug discovery | 7 |
potent human | 7 |
relatively low | 7 |
medical students | 7 |
molecular genotyping | 7 |
repose sur | 7 |
cmap amplitude | 7 |
iatrogenic blood | 7 |
clinical specimens | 7 |
health security | 7 |
inflammatory cytokines | 7 |
clr concentrations | 7 |
related failed | 7 |
infected patient | 7 |
mosquito population | 7 |
reticulum stress | 7 |
negative antibody | 7 |
regulatory requirements | 7 |
potential association | 7 |
virus envelope | 7 |
infectious pathogens | 7 |
molecular tweezers | 7 |
analysis showed | 7 |
specific cd | 7 |
published literature | 7 |
culex quinquefasciatus | 7 |
broad range | 7 |
procedures performed | 7 |
based potentiometric | 7 |
commodity waste | 7 |
htlv ii | 7 |
york blood | 7 |
care professionals | 7 |
virus isolation | 7 |
new technology | 7 |
additional studies | 7 |
several months | 7 |
different clr | 7 |
retest options | 7 |
partial protection | 7 |
rh confirmation | 7 |
den driessche | 7 |
vaccine efficacy | 7 |
ai applications | 7 |
laboratory medicine | 7 |
antibodies elicited | 7 |
future state | 7 |
unit transfusion | 7 |
persistently infected | 7 |
protective immunity | 7 |
positive rbcs | 7 |
clerical errors | 7 |
seven days | 7 |
congenital hcmv | 7 |
nonstructural proteins | 7 |
cfu ml | 7 |
lung injury | 7 |
current evidence | 7 |
untreated control | 7 |
big data | 7 |
dexamethasone withdrawal | 7 |
mg ml | 7 |
enhanced automation | 7 |
hemoglobin level | 7 |
analysis resource | 7 |
developed countries | 7 |
salivary glands | 7 |
preterm delivery | 7 |
cell membrane | 7 |
virus shedding | 7 |
infection damages | 7 |
reduce zikv | 7 |
fetal microcephaly | 7 |
inhibiting zikv | 7 |
virus pathogen | 7 |
function research | 7 |
sequence data | 7 |
esd implementation | 7 |
mutagenic activity | 7 |
healthcare system | 7 |
prise en | 7 |
isotype control | 7 |
globally asymptotically | 7 |
wireless sensor | 7 |
hemorrhagic shock | 7 |
drain current | 7 |
clinical disease | 7 |
prevent transfusion | 7 |
en france | 7 |
zikv molecular | 7 |
primary antibody | 7 |
i cv | 7 |
routinely used | 7 |
become pregnant | 7 |
hospital customers | 7 |
serial passage | 7 |
quantitative pcr | 7 |
automatic appointment | 7 |
control samples | 7 |
abnormal risk | 7 |
existing immunity | 7 |
cell concentrates | 7 |
epidemic areas | 7 |
high level | 7 |
babesia microti | 7 |
expert systems | 7 |
genetic diversity | 7 |
increased walk | 7 |
bank testing | 7 |
received ivig | 7 |
onset disease | 7 |
tetravalent dengue | 7 |
electronic ordering | 7 |
transfusion protocols | 7 |
risks associated | 7 |
prediction algorithm | 7 |
hearing loss | 7 |
two samples | 7 |
global public | 7 |
test result | 7 |
rhce variants | 7 |
oxygen delivery | 7 |
prospective cohort | 7 |
computer program | 7 |
autochthonous transmission | 7 |
ag mouse | 7 |
surveillance system | 7 |
baseline data | 7 |
reduction neutralization | 7 |
reactive antibodies | 7 |
transfused per | 7 |
mean number | 7 |
infection control | 7 |
tubing segments | 7 |
fluorescence signal | 7 |
tested mabs | 7 |
microvascular endothelial | 7 |
rh haplotypes | 7 |
genome copy | 7 |
wbc ul | 7 |
panel cells | 7 |
denv ediii | 7 |
zikv immunodetection | 7 |
abbott diagnostics | 7 |
emergency committee | 7 |
emerging diseases | 7 |
dtt treated | 7 |
donor deferrals | 7 |
background information | 7 |
findings suggested | 7 |
immunosorbent assay | 7 |
transfusion guidelines | 7 |
least two | 7 |
short term | 7 |
higher rates | 7 |
epidemic potential | 7 |
virus causes | 7 |
well plate | 7 |
samples showed | 7 |
staphylococcus aureus | 7 |
zika patient | 7 |
lateral ridge | 7 |
mouse brain | 7 |
des patients | 7 |
virus targets | 7 |
clinical significance | 7 |
exchange transfusion | 7 |
microglial cells | 7 |
zimmer biomet | 7 |
inactivated virus | 7 |
job aid | 7 |
human induced | 7 |
converting enzyme | 7 |
detection system | 7 |
false positives | 7 |
leydig cells | 7 |
zikv genome | 7 |
university medical | 7 |
oxidative stress | 7 |
clinical laboratory | 7 |
predictive value | 7 |
viruses zika | 7 |
cell transfusion | 7 |
study day | 7 |
dependent rna | 7 |
will need | 7 |
priority behaviors | 7 |
possible zika | 7 |
passive transfer | 7 |
sgs assembly | 7 |
viral envelope | 7 |
infected pregnant | 7 |
small numbers | 7 |
inflammatory cells | 7 |
population immunity | 7 |
may present | 7 |
health background | 7 |
cancer center | 7 |
controlled trials | 7 |
sporadic cases | 7 |
index donations | 7 |
base station | 7 |
health preparedness | 7 |
identified natural | 7 |
blood units | 7 |
abo discrepancy | 7 |
platelet collection | 7 |
continued pressures | 7 |
urgent need | 7 |
dans le | 7 |
higher levels | 7 |
may represent | 7 |
neonatal intensive | 7 |
remote blood | 7 |
infected mosquitoes | 7 |
des signes | 7 |
human disease | 7 |
blood bags | 7 |
walk away | 7 |
also important | 7 |
potent neutralization | 7 |
journal articles | 7 |
dara treatment | 7 |
different viral | 7 |
antibody testing | 7 |
exclude concomitant | 7 |
diagnostic samples | 7 |
basic health | 7 |
group received | 7 |
induced damage | 7 |
based zikv | 7 |
year post | 7 |
treatment time | 6 |
viral spread | 6 |
laboratory diagnosis | 6 |
bacterial meningitis | 6 |
also called | 6 |
vivo protection | 6 |
virus stocks | 6 |
rhd allele | 6 |
also found | 6 |
confidence intervals | 6 |
infusion pump | 6 |
human rights | 6 |
fetal infection | 6 |
products ordered | 6 |
i trauma | 6 |
health information | 6 |
secondary tma | 6 |
specific antiviral | 6 |
products collected | 6 |
warm autoimmune | 6 |
observed increase | 6 |
organ transplants | 6 |
emergency room | 6 |
dna testing | 6 |
high quality | 6 |
phosphatidylserine exposure | 6 |
constant regions | 6 |
zoonotic diseases | 6 |
graphpad software | 6 |
also includes | 6 |
mouse anti | 6 |
natural phenol | 6 |
new emerging | 6 |
cardiovascular surgery | 6 |
dried plasma | 6 |
automated result | 6 |
fetal bovine | 6 |
ordering practices | 6 |
pcr system | 6 |
giving rise | 6 |
targeted antibodies | 6 |
congenital cmv | 6 |
first recognized | 6 |
bleeding patients | 6 |
increasing number | 6 |
zikv persistence | 6 |
epidemiological data | 6 |
fresh levels | 6 |
timely manner | 6 |
final volume | 6 |
clinical syndromes | 6 |
high mortality | 6 |
platelet loss | 6 |
assess whether | 6 |
infect dis | 6 |
infected group | 6 |
virus isolates | 6 |
supplemental testing | 6 |
gene sequence | 6 |
maternal infection | 6 |
virus neutralization | 6 |
digital disease | 6 |
potential risks | 6 |
bone needle | 6 |
conformational changes | 6 |
will also | 6 |
four serotypes | 6 |
platelet donations | 6 |
retrospective chart | 6 |
laboratory capacity | 6 |
data available | 6 |
transfusion transmission | 6 |
platelet cd | 6 |
del zika | 6 |
animal care | 6 |
aptamer paper | 6 |
pregnant females | 6 |
comfort level | 6 |
washed three | 6 |
hepatocellular carcinoma | 6 |
cell suspension | 6 |
cell therapy | 6 |
mammalian cell | 6 |
prevalence antigen | 6 |
platelet concentration | 6 |
six months | 6 |
golgi apparatus | 6 |
third party | 6 |
multiple studies | 6 |
eea countries | 6 |
kit ii | 6 |
highly effective | 6 |
whether clr | 6 |
may cause | 6 |
health impact | 6 |
post hoc | 6 |
sequence similarity | 6 |
new insights | 6 |
dna viruses | 6 |
critical care | 6 |
first week | 6 |
basic training | 6 |
factor xiii | 6 |
citrate toxicity | 6 |
antibody formation | 6 |
described previously | 6 |
transmission events | 6 |
three years | 6 |
virus infectivity | 6 |
bank information | 6 |
pizv doses | 6 |
mice without | 6 |
ed bakker | 6 |
parasites ml | 6 |
allogeneic donors | 6 |
detection using | 6 |
transfusion strategies | 6 |
uv fluorescence | 6 |
development zika | 6 |
lateral ventricles | 6 |
lactate dehydrogenase | 6 |
dengue serotypes | 6 |
significantly reduces | 6 |
lower risk | 6 |
zikv full | 6 |
whole virus | 6 |
spotted fever | 6 |
cell separators | 6 |
buccal swabs | 6 |
routine clinical | 6 |
zoster virus | 6 |
rhd sequencing | 6 |
central venous | 6 |
mtor inhibitors | 6 |
time frame | 6 |
table shows | 6 |
leading cause | 6 |
high dose | 6 |
antigen positive | 6 |
plasma pas | 6 |
platforms capable | 6 |
virus evolution | 6 |
growth factors | 6 |
antiviral therapies | 6 |
bis tage | 6 |
infection causes | 6 |
four dengue | 6 |
hpa antibodies | 6 |
uc tissue | 6 |
small volume | 6 |
qualtex laboratories | 6 |
bank staff | 6 |
low cost | 6 |
health systems | 6 |
wbc counts | 6 |
epidemic spread | 6 |
avis relatif | 6 |
virus via | 6 |
transfusion volume | 6 |
low frequency | 6 |
viral inactivation | 6 |
prevent unnecessary | 6 |
search queries | 6 |
rational design | 6 |
inclusion criteria | 6 |
induced pluripotent | 6 |
individuals infected | 6 |
counter measures | 6 |
causes birth | 6 |
molecular sieving | 6 |
months later | 6 |
clinical study | 6 |
developmental delays | 6 |
clinical course | 6 |
edible plants | 6 |
south china | 6 |
evidence based | 6 |
decidual immune | 6 |
zika viral | 6 |
diagnostic kits | 6 |
emerging infections | 6 |
transfusion therapy | 6 |
sensitivity analysis | 6 |
sigma aldrich | 6 |
performed within | 6 |
virus persistence | 6 |
insect repellents | 6 |
rhce gene | 6 |
electronic system | 6 |
specific neutralizing | 6 |
silver paint | 6 |
usaid implementing | 6 |
wbc concentration | 6 |
free state | 6 |
patient rbcs | 6 |
contact information | 6 |
pilot period | 6 |
donors may | 6 |
total protein | 6 |
frozen storage | 6 |
institutional review | 6 |
plt ct | 6 |
avec une | 6 |
ko mice | 6 |
automated attendant | 6 |
transfusion sample | 6 |
information systems | 6 |
test battery | 6 |
abbott laboratories | 6 |
among humans | 6 |
supply program | 6 |
mediated endocytosis | 6 |
current zika | 6 |
statistical analyses | 6 |
ngs methods | 6 |
human pathogens | 6 |
cv access | 6 |
structural biology | 6 |
central blood | 6 |
global response | 6 |
dna extraction | 6 |
zikv pathogenesis | 6 |
target cells | 6 |
donor units | 6 |
condom use | 6 |
will provide | 6 |
enrichment sequencing | 6 |
level trauma | 6 |
local blood | 6 |
vector laboratories | 6 |
hoec cells | 6 |
infected human | 6 |
serine protease | 6 |
experiments involving | 6 |
transcription pcr | 6 |
eye drops | 6 |
type iii | 6 |
will help | 6 |
related complications | 6 |
international health | 6 |
care hospital | 6 |
funding agencies | 6 |
relatively small | 6 |
diagnostics background | 6 |
european centre | 6 |
approved drug | 6 |
genetic testing | 6 |
pic kel | 6 |
cardiac troponin | 6 |
new drug | 6 |
promising candidate | 6 |
human volunteers | 6 |
health regulations | 6 |
reading frame | 6 |
recurrent episodes | 6 |
intrinsically disordered | 6 |
highly potent | 6 |
joint pain | 6 |
new method | 6 |
transmission may | 6 |
cells via | 6 |
hour post | 6 |
treated rrbc | 6 |
donor recruitment | 6 |
igm igg | 6 |
arachidonic acid | 6 |
hospitalization isolation | 6 |
closed conformation | 6 |
cell counter | 6 |
units tested | 6 |
rhd dar | 6 |
novel viruses | 6 |
infected male | 6 |
varying degrees | 6 |
fungal infections | 6 |
blood types | 6 |
assay provided | 6 |
limited countries | 6 |
complete viral | 6 |
negative rbc | 6 |
dengue infectivity | 6 |
primary antibodies | 6 |
human decidual | 6 |
also noted | 6 |
immunocompetent mice | 6 |
performance characteristics | 6 |
jackson immunoresearch | 6 |
inhibit viral | 6 |
molecular analysis | 6 |
rbc order | 6 |
mild disease | 6 |
von bis | 6 |
commons attribution | 6 |
recent ebola | 6 |
autologous plasma | 6 |
human cell | 6 |
state university | 6 |
ct plts | 6 |
laboratories background | 6 |
also determined | 6 |
days following | 6 |
neonatal microcephaly | 6 |
treated pcs | 6 |
antimalarial drug | 6 |
total plasma | 6 |
haemorrhagic fever | 6 |
cell lymphoma | 6 |
littermate neonates | 6 |
malaria parasite | 6 |
shown previously | 6 |
ebola vaccine | 6 |
strains isolated | 6 |
new technologies | 6 |
high viral | 6 |
neutralization assay | 6 |
platelet fraction | 6 |
tfn hct | 6 |
biotin interference | 6 |
plasma transfusion | 6 |
production pools | 6 |
small molecule | 6 |
transfused rbcs | 6 |
using flow | 6 |
past years | 6 |
human populations | 6 |
manual gel | 6 |
african strain | 6 |
collected using | 6 |
rbcs transfused | 6 |
without affecting | 6 |
iu dose | 6 |
infection also | 6 |
glial cells | 6 |
cell monolayers | 6 |
clinical application | 6 |
human challenge | 6 |
matched controls | 6 |
du chikungunya | 6 |
dengue transmission | 6 |
specific human | 6 |
also identified | 6 |
thioglycolic acid | 6 |
inactivated vaccines | 6 |
diagnostic capacity | 6 |
mise en | 6 |
virus outbreaks | 6 |
add ml | 6 |
acute zikv | 6 |
transmission zika | 6 |
thermo scientific | 6 |
internal medicine | 6 |
total human | 6 |
molecular evolution | 6 |
wb units | 6 |
buccal swab | 6 |
weeks later | 6 |
vitro studies | 6 |
first line | 6 |
treatment group | 6 |
storage conditions | 6 |
maternal viremia | 6 |
mortality rates | 6 |
target antigen | 6 |
taken together | 6 |
variable regions | 6 |
higher incidence | 6 |
infected population | 6 |
like particles | 6 |
ml penicillin | 6 |
fda guidance | 6 |
fetal harm | 6 |
statistically different | 6 |
cell type | 6 |
congenital microcephaly | 6 |
six sigma | 6 |
chronic hepatitis | 6 |
mass gatherings | 6 |
information provided | 6 |
supplementary material | 6 |
african lineage | 6 |
infected ag | 6 |
population health | 6 |
viral membrane | 6 |
aedes africanus | 6 |
donors tested | 6 |
subsequently transfused | 6 |
ml whole | 6 |
term water | 6 |
available data | 6 |
cell counting | 6 |
confirmatory testing | 6 |
error catastrophe | 6 |
significantly associated | 6 |
mononuclear cell | 6 |
storage time | 6 |
us studies | 6 |
mutagenic drugs | 6 |
neurite extension | 6 |
suspected congenital | 6 |
three independent | 6 |
index donation | 6 |
study investigated | 6 |
cell phenotype | 6 |
health seeking | 6 |
early pregnancy | 6 |
culture bottles | 6 |
macaque model | 6 |
cytometric analysis | 6 |
using minitab | 6 |
activated protein | 6 |
incidental findings | 6 |
chikungunya fever | 6 |
three months | 6 |
molecular determinants | 6 |
igg antibodies | 6 |
transfusion yield | 6 |
data streams | 6 |
initial reactive | 6 |
troponin i | 6 |
preliminary data | 6 |
scid mice | 6 |
mouth disease | 6 |
yet another | 6 |
sample pairs | 6 |
total volume | 6 |
host disease | 6 |
every minutes | 6 |
may allow | 6 |
cd antigen | 6 |
behavior prioritization | 6 |
treatment groups | 6 |
gel cards | 6 |
surgical research | 6 |
automated testing | 6 |
neglected diseases | 6 |
genetic analysis | 6 |
heel stick | 6 |
technical staff | 6 |
convalescent patient | 6 |
plasma reacted | 6 |
also assessed | 6 |
transfusion laboratory | 6 |
virus inoculation | 6 |
log reduction | 6 |
reproductive age | 6 |
phenotypically matched | 6 |
three zikv | 6 |
infected mouse | 6 |
viral life | 6 |